Search results
Author(s):
Marti L McCulloch
,
Robert J Davis
Added:
3 years ago
The cardiac imaging field has experienced significant improvements over the last decade due to technological advances. Cardiac computed tomography (CT), cardiac magnetic resonance imaging (MRI), nuclear cardiology, and echocardiography have all become feasible imaging modalities for physicians to evaluate in order to answer specific diagnostic questions. Each of the aforementioned modalities has…
View more
Author(s):
Ziad A Ali
Added:
7 months ago
ESC 2023 — Dr Ziad Ali (DeMatteis St Francis, US) joins us to discuss the findings from the ILUMIEN IV clinical trial (NCT03507777).
ILUMIEN IV (Abbott Medical Devices)is a prospective, single-blind clinical trial aiming to compare optical coherence tomography (OCT) to an angiography-guided stent implantation strategy. The trial investigated which method achieved a larger post-percutaneous…
View more
Author(s):
Paul Kalra
Added:
1 year ago
Iron deficiency is common in heart failure, particularly in hospitalised patients and may exacerbate symptoms and increase the risk of hospitalisation and premature mortality. Although previous studies have shown that intravenous iron provides improvement in exercise capacity and reduces hospitalisation in patients with HF and iron deficiency, longer term efficacy and safety data has been lacking…
View more
Author(s):
Pim van der Harst
,
Added:
1 year ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Pim van der Harst and Dr Marie-Sophie de Koning (University Medical Center Groningen, NL) discuss the data from the GIPS-IV trial which investigates the safety and efficacy of the hydrogen sulfide (H2S) donor sodium thiosulfate (STS) in patients presenting with ST-segment elevation myocardial infarction (STEMI) …
View more
Author(s):
Rawan Amir
,
Paul Kalra
Added:
1 year ago
AHA 22 - Dr Rawan Amir, CardioNerds Fellow (Johns Hopkins Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Paul Kalra (Portsmouth Hosp Univ NHS Trust, UK), investigator of the late-breaking IRONMAN trial (NCT02642562).
This randomised, open-label multicentre trial assessed the effectiveness of intravenous iron treatment compared to…
View more
Author(s):
Lars H Lund
Added:
1 year ago
In this short interview from HF 22, Prof Lars Lund (Karolinska Institute, Stockholm, SE) joins us on-site to discuss the outcomes of the Ghrelin-HF study. This was a placebo controlled, randomised trial that evaluated the effects of intravenous ghrelin in patients with heart failure with preserved ejection fraction (HFpEF).
Discussion Points:
Aims of This Study
Mechanism of Action
Patient…
View more
Author(s):
John GF Cleland
Added:
10 months ago
ESC-HFA 23 - Prof John Cleland (University of Glasgow, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
IRONMAN was a randomised, open-label multicenter trial, which aimed to assess the effectiveness of intravenous iron in patients with heart failure and iron deficiency as compared to standard care. It demonstrated that the administration of IV FDI was associated with lower rates…
View more
Nina Wunderlich
Job title: Head of Noninvasive Cardiology
Author
Author(s):
Paul Kalra
Added:
10 months ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and…
View more
Christos G Mihos
Job title: Director
Author